Baxter Bioscience

Baxter’s BioScience business is a leader in recombinant and plasma-based protein replacement therapies to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products and developmental technology used in adult stem-cell therapies; and vaccines. BioScience core franchises include: Hemophilia, Biotherapeutics, BioSurgery and Vaccines. BioScience products represent approximately 45 percent of Baxter’s annual sales, totaling $5.7 billion in 2010. BioScience is a fully integrated business and includes discovery, development, manufacturing and operations, and commercial businesses in the areas of coagulation therapies, immune globulins for immune disorders, treatment for alpha 1-antitrypsin deficiency, vaccines and therapies for wound healing and treatments for shock.

show less